LAL2000: Adult ALL Treatment at Diagnosis

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto (Other)

Overall Status

Completed

CT.gov ID

NCT00537550

Collaborator

(none)

Locations

Duration (Months)

Study Details

Study Description

Brief Summary

The present study has been designed to give participating centers the possibility of better understanding the diagnostic and prognostic factors of ALL patients.

Condition or Disease	Intervention/Treatment	Phase
Leukemia, Lymphocytic, Acute	Drug: Vincristine Drug: Vincristin, Daunorubicine, Asparaginase, Methotrexate	N/A

Study Design

Study Type:

Interventional

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

GIMEMA Guidelines for the Treatment of Adult ALL Affected Patients at Diagnosis

Study Start Date :

Jul 1, 2000

Actual Study Completion Date :

Jun 1, 2006

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

14 Years to 60 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Diagnosis of acute lymphoblastic leukemia (ALL)
Negative myeloperoxidase stain
Phenotype T (ALL-T) and B(ALL-B)

Exclusion Criteria:

Creatinine > 2.5mg/dL after adequate hydratation
LVEF <50%
Presence of documented infections not responding to antibiotic and/or antifungal therapy
Presence of concomitant malignant diseases
Absence of any psychological condition that does not allow to intake high doses of cortisone
Patients who have received any antineoplastic chemiotherapy for more than 5 days
Patients who have received any steroids for more than 10 days

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Az. Ospedaliera S. G. Moscati	Avellino	Italy
2	Ist.Ematologia e Oncologia Medica L.e A. Seragnoli	Bologna	Italy
3	Ospedale Reg. A di Summa	Brindisi	Italy
4	Istituto di Ematologia- Ospedale San Carlo	Potenza	Italy
5	Policlinico G.B. Rossi	Verona	Italy	37134